Hints and tips:
Related Special Reports
...Powell said investors worried that Pfizer had paid a lot for what it had bought....
...Because the European market is saturated with the BioNTech/Pfizer and Moderna shots, it remains unclear what impact on its revenues an approval might have....
...Pfizer declined to comment, citing confidentiality, as did the Commission....
...The US pharmaceutical company has agreed to extend its contract from 2023 to 2026, according to two people with knowledge of the talks....
...wants a pivot in the biotech’s sales strategy for its Covid-19 shot, which is based on traditional vaccine technology, to target older people unnerved by rare side effects associated with mRNA jabs from Pfizer...
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
...In response to these concerns, Pfizer initiated a significant cost-cutting programme, worth at least $4bn....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...Yet Pfizer’s $19bn in Paxlovid sales were almost a fifth of its 2022 total....
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
...BioNTech has written down about €900mn on its Covid-19 vaccines because of lower than expected demand for the shots it developed with partner Pfizer....
...US prosecutors have charged a former Pfizer employee, a Massachusetts police chief, a former pharmaceutical executive and investors in a Donald Trump media venture in separate insider trading cases, as part...
...Pfizer will keep the commercialisation rights outside the US and Japan. Roivant owns 75 per cent of Telavant, while Pfizer owns 25 per cent....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Shares in Pfizer added about 1 per cent on Friday, while Seagen was up about 0.9 per cent....
...A senior Pfizer executive has warned that a crackdown on mergers and acquisitions by antitrust regulators would be a “disaster” for the system of innovation that underpins the pharmaceutical industry....
...The new rules give the federal government the power to negotiate lower prices for some of the most expensive prescription drugs produced by Pfizer, Merck and other pharma companies purchased by Medicare,...
...The company, whose four approved oncology treatments generated $2bn in sales last year, should help the pharmaceutical company offset some of an expected decline in revenue as the Covid vaccine boom fades...
...Pfizer said its acquisition of Seagen — the largest pharmaceutical deal agreed since 2019 — would contribute more than $10bn in 2030 risk-adjusted revenues, with potential significant growth beyond 2030....
...The drugmakers Pfizer and Roche said they are piloting use of rFC at some of their facilities....
...US pharmaceutical company Pfizer sold the shots, developed with Germany’s BioNTech, for about $19 a dose under the contract signed in 2021, but the new price has not been disclosed....
...Pfizer has agreed to acquire oncology-focused biotech Seagen for a total enterprise value of $43bn as the US pharmaceutical company refills its drugs pipeline amid a sharp fall in sales of its Covid-19 products...
...Given that close to three-quarters of the 224mn vaccine doses administered in Germany were produced by BioNTech in collaboration with Pfizer, the vast majority of the claims are being brought against the...
International Edition